← Eichor
Study identifier: NCT07262606 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Salivary Mitofusin-1 Levels in Periodontitis: Associations With Disease Severity, Smoking, and Treatment Response

Condition: Periodontal Disease · Chronic Periodontitis (Disorder)  ·  Sponsor: Ömer Faruk Okumuş

PhaseNA
Planned participants104
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersYes

About this study

Periodontitis (gum inflammation) is a common disease worldwide. This study aims to investigate a novel biomarker, a protein called Mitofusin-1 (Mfn1), in saliva that may be associated with the severity of periodontitis and response to treatment. The study will include periodontally healthy individuals, individuals with mild to severe periodontitis, and smokers with severe periodontitis. Participants will receive saliva samples and undergo clinical periodontal examinations. Individuals with periodontitis will receive standard periodontal treatment, and changes in Mfn1 levels will be assessed 3 months after treatment. The study is expected to shed light on the potential utility of Mfn1 as a marker in the diagnosis and follow-up of periodontitis.

This description comes directly from the study's public registry record.

Talk to the study team

Ömer F. Okumuş, DDS,PhD  ·  05532140969  ·  okumus.omer24@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Erzincan Binali Yıldırım University Faculty of DentistryErzincan, Erzincan, Turkey (Türkiye)Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07262606